Endoxifen program into rare pediatric neuromuscular disease along with previously received Rare Pediatric Disease Designation SEATTLE, /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa ...
Without fanfare, the bill on union transparency and governance was amended just before the holiday break. And the union ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback